INC Invests in Technology Innovation with the DrugDev Golden Number and Patient Engagement

 technology has been used directly by leading pharmaceutical companies to improve how their clinical trials are run. In order to advance collaboration and standardization that drive benefits throughout the industry and enable companies to do more trials, the company has launched its CRO Preferred Partner program alongside Charter Member INC Research.	 	When sponsors work with a Preferred Partner such as INC, they have the confidence that their selected CRO is a trustworthy expert with real-world experience using DrugDev’s SaaS tools to supplement or enhance the value of their provided services.	 	As a Charter Member of the program, INC Research was 

the first CRO to standardize on the DrugDev Golden Number

, the unique identifier that powers the TransCelerate Investigator Registry and Investigator Databank. The DrugDev Golden Number is used to match and master data from disparate sources (including INC's internal experience and DrugDev’s Investigator Network) to enable superior evidence-based decisions related to study planning and site identification. This means that when sponsors partner with INC, they are leveraging the same mastered profiles for more than 500,000 global site staff and facility providers.	 	INC also offers sponsors use of the new DrugDev patient engagement solution, which enables sites to send reminders, documents and notifications to patients via SMS, and provides patients with a comfortable online home for all their study information – using an intuitive interface on a desktop computer or mobile app.	 	“As an innovation leader, INC Research is committed to investing in solutions that enable us to deliver better and more efficient services for our pharmaceutical customers,” said Jonathan Shough, Chief Information Officer at INC Research. “We applaud industry-wide collaborative efforts and are proud to be integrated with the DrugDev Golden Number, and to provide our sponsors with direct access to the latest patient engagement solutions.”	 	“Thankfully, our entire industry has realized that it is no longer acceptable for any company simply to make their trials a little bit better or a little bit faster,” said Ibraheem “Ibs” Mahmood, President and CEO of DrugDev. “We have a collective responsibility to families around the world to dramatically change how we do business, so we can do more trials and bring more helpful therapies – not just a few, but loads and loads of them – to market. The only way to accomplish this is for sponsors, CROs and vendors to work together using common systems with consistent data models and user experiences. Visionary companies such as INC are leading the way and we are honored that they have adopted DrugDev technology so we can continue to transform clinical trials together.”